Abstract: Epithelial barriers play an important role in regulating mucosal homeostasis. Upon injury, the epithelium and immune cells orchestrate repair mechanisms that reestablish homeostasis. This process is highly regulated by protein and lipid mediators such as Annexin A1 (ANXA1). In this review, we focus on the pro-repair properties of ANXA1.
Introduction
Epithelial barriers interface external environment and tissue compartments. Thus injury to this barrier can have detrimental effects on tissue homeostasis. Efficient resealing of such injuries or wounds is critical for not only re-establishing the epithelial barrier, but also in the resolution of inflammation and restoration of mucosal homeostasis. Following injury, epithelial cells migrate and proliferate to repair denuded mucosal surfaces. Inflammatory cells are recruited to sites of injury where they not only contribute to host defense but also actively participate in repair of epithelial wounds. A number of pro-resolving mediators are released from the leukocytes as well as the epithelium into the wound bed where they orchestrate tissue repair. In this review we focus on the pro-resolving mediator Annexin A1 (ANXA1), which has been shown to have therapeutic effects in promoting mucosal wound repair.
ANXA1: a pro-resolving mediator
The inflammatory phase is an essential component of mucosal tissue repair. Mucosal injury is associated with rapid onset of inflammation, which increases over the subsequent few days and then subsides. The inflammatory response and wound repair are delicately balanced to ensure restoration of mucosal homeostasis. In chronic inflammatory diseases, such resolution of inflammation is compromised, resulting in sustained inflammation and impaired wound healing (Fullerton and Gilroy, 2016) .
Following injury, pro-resolving mediators that include lipids (lipoxins, resolvins, protectins, and maresins) and proteins such as ANXA1 are released into the epithelial milieu to orchestrate clearance of inflammation, wound repair and restoration of mucosal homeostasis (Serhan, 2014; Leoni et al., 2015c) . Pro-resolving mediators achieve these functions by a number of mechanisms that include decreased endothelial activation, reduced leukocyte infiltration, and activation of neutrophil apoptosis by scavenger macrophages through efferocytosis (Ortega-Gomez et al., 2013; Serhan, 2014; Basil and Levy, 2016) .
ANXA1 is a 37 kDa calcium-and phospholipid-binding protein expressed in monocytes, macrophages, neutrophils and epithelial cells (Flower and Rothwell, 1994; Babbin et al., 2007) . It is regulated by glucocorticoids (CGs) and has been reported to mediate their anti-inflammatory activity (Croxtall and Flower, 1994; Taylor et al., 1994; Perretti et al., 1996) . GCs not only induce the ANXA1 gene but also increase secretion of the protein from existing intracellular pools by stimulating PKC activity (Solito et al., 2003) .
ANXA1 exerts its biological responses by activating Formyl peptide receptors (FPRs) (Perretti, 2003; Perretti and D'Acquisto, 2009 ). The three human FPRs (FPR1, FPR2/ALX, and FPR3) are G protein-coupled receptors that share significant sequence homology (Ye et al., 2009) . While function of these receptors has been extensively explored in leukocytes, recent studies have addressed the contribution of FPR signaling in mediating repair of epithelial surfaces (Babbin et al., 2007; Wentworth et al., 2010 Wentworth et al., , 2011 Leoni et al., 2013 Leoni et al., , 2015a Alam et al., 2014) . Several pro-and anti-inflammatory ligands bind FPR1 and FPR2/ALX (Le et al., 2002) . The biological response of the ANXA1 protein and its cleavage product Ac2-26 peptide are mediated by FPR1 and FPR2/ALX (Perretti et al., 2002; Perretti, 2003; Leoni et al., 2015a) . Intestinal epithelial cells express ANXA1 and its receptors (FPR1 and FPR2/ALX). Shown in Figure 1 is the expression of these proteins at the leading edge of epithelial cells migrating to reseal a wound (the authors used NFPR1 Ab to identify the expressions of FPR1 and FPR2/ALX, Riesselam et al., 2007) . Cooray and coworkers reported FPR2/ALX homodimerization and activation of p38 mitogen-activated protein kinase signaling by the full-length ANXA1 protein.
In contrast Ac2-26 promotes hetero-dimerization of FPR1 and FPR2/ALX, and activation of c-Jun N-terminal kinase (JNK)-signaling (Cooray et al., 2013) . We recently demonstrated that endogenous ANXA1 is released as a component of extracellular vesicles (EVs) derived from intestinal epithelial cells, and ANXA1 EVs activate mucosal wound repair circuits (Leoni et al., 2015b) . EVs are emerging as important mechanisms of intercellular communication by transferring proteins and other cellular components to target cells. Thus, ANXA1 derived from wound associated cells, including leukocytes and epithelial cells, exerts paracrine and autocrine effects on the epithelium to facilitate wound closure and enhance barrier recovery (Babbin et al., 2006 (Babbin et al., , 2008 Leoni et al., 2013) . In addition to naturally occurring ANXA1 in EVs, hydrogels containing ANXA1 peptide mimetic Ac2-26 have been generated and shown to promote wound repair (Del Gaudio et al., 2015) .
ANXA1 facilitates resolution of inflammation and repair by a number of mechanisms that include inhibition of leukocytes recruitment by decreasing their adhesion/ recruitment and transmigration (Mancuso et al., 1995; Getting et al., 1997; Chatterjee et al., 2005) . Interestingly, anti-allergic drugs referred to as cromones induce the release of ANXA1, which decreases neutrophil recruitment (Yazid et al., 2010) . Hydrogen sulfide (H 2 S), a gaseous mediator increased during sepsis and under inflammatory conditions also promotes ANXA1 mobilization, which in turn controls leukocyte trafficking (Brancaleone et al., 2014) . The existence of this positive loop between ANXA1 and H 2 S represents an important mechanism which harnesses the biological properties of this gaseous mediator.
McArthur and colleagues identified a novel mechanism by which ANXA1 released from apoptotic neutrophils recruits monocytes that clear apoptotic cells thereby protecting the surrounding healthy tissue (McArthur et al., 2015) . ANXA1 induces a favorable macrophage M2a phenotype that release interleukin-10 and TGFβ (Li et al., 2011) . In line with these results, ANXA1 administration suppressed M1 activation of liver macrophages. Interestingly, ANXA1 skewed M1 macrophages to anti-inflammatory M2-like cells, attenuating the expression of IL-6, IL-1β, and TNF-α (Li et al., 2011) . Additionally, ANXA1 and its receptor FPR2/ALX have been reported to promote transition of pro-inflammatory M1 macrophages in the acute phase of renal injury to anti-inflammatory M2 macrophages in the chronic phase of disease (Zhang et al., 2012; Locatelli et al., 2014) . ANXA1 and its mimetic peptide increase the clearance rate of apoptotic neutrophils by human macrophages also referred to as efferocytosis (Maderna et al., 2005; Blume et al., 2012) . ANXA1-null mice provided further evidence for a functional role of ANXA1 in efferocytosis, as bone marrow derived macrophages from these mice were defective in clearance of apoptotic cells (Maderna et al., 2005) . Another study confirmed the importance of ANXA1 expression on macrophages derived from bone marrow and involved in the recognition and phagocytosis of apoptotic neutrophils (Dalli et al., 2012) . Recent studies have identified apoptosis as an important host defense mechanism against microbial infection. ANXA1 absence is in fact correlated with reduced phagocytosis in the presence of bacterial and fungal particles (Yona et al., 2006) . These properties confirm the importance of ANXA1 and Ac2-26 in mediating host defense and resolution of inflammation (Buckley et al., 2014; Serhan, 2014; Vago et al., 2016) . Additionally, ANXA1 contributes to the transfer of antigens from apoptotic vesicles to dendritic cells for activation of CD8 + T cells (Tzelepis et al., 2015) . ANXA1 in fact, controls the immune response to mycobacterium tuberculosis infection (Tzelepis et al., 2015) . A recent study also identified release of ANXA1 by murine macrophages expressing purigenic P2X7 receptor that contribute to its pro-resolving response (de Torre-Minguela et al., 2016) . In addition to the cell types mentioned above, ANXA1 is expressed in brain microvascular endothelial cells and regulates blood-brain barrier (BBB) integrity. ANXA1 knockout mice show significantly increased BBB permeability that is associated with compromised function of endothelial tight and adherens junctions (Cristante et al., 2013) . Furthermore, ANXA1 influences mast cell response in inflammation by limiting their degranulation and activation (Sinniah et al., 2016) . In summary, ANXA1 and its receptors on epithelial cells, macrophages, neutrophils, endothelial cells and mast cells represent important targets for pro-resolution pathways in diseases involving inflammation and tissue injury.
ANXA1 as a potential therapeutic tool to reduce mucosal inflammation
Chronic inflammatory disorders such as inflammatory bowel disease (IBD) encompassing ulcerative colitis (UC) and Crohn's disease (CD) are characterized by compromised epithelial barrier function, aberrant inflammatory response and mucosal wounds (Cosnes et al., 2011) . Analysis of mucosal tissue from UC patients implicates a relationship between ANXA1 secretion and severity of the inflammatory response (Vergnolle et al., 2004; Vong et al., 2012) . Previous studies have demonstrated that ANXA1 is localized in neutrophils in biopsies of human patients with active disease and in macrophages during the disease remission (resolution phase). Reduction of pro-inflammatory cytokine TNF-α signaling has been observed to amplify ANXA1 levels in the intestinal mucosa. Furthermore, biopsies from UC patients with anti-TNF-α therapy during disease remission revealed increased mucosal ANXA1 protein. Additionally, TNF-α inhibition increased ANXA1 expression in the intestinal epithelium and promoted resolution of inflammation in a murine colitis model (Sena et al., 2015) . Interestingly, ANXA1 knockout mice have increased susceptibility to dextran sulfate sodium (DSS) -induced colitis and delayed recovery from colitis (Leoni et al., 2013) . ANXA1 suppresses indomethacin-induced leukocyte adherence to the vascular endothelium (Zanardo et al., 2005) further supporting its role in resolution of inflammation. Another ANXA1 peptide, MC-12 has been reported to have beneficial effects in suppressing NF-κB-dependent inflammatory signaling (Ouyang et al., 2012) . Treatment with MC-12, inhibited the inflammatory response and promoted repair in the intestinal mucosa (Ouyang et al., 2012) .
The therapeutic effects of ANXA1 were observed during the resolution and repair phase of colitis as reported above. This pro-repair response of ANXA1 in the intestinal epithelium was mediated by activation of a small GTPase Rac1 and epithelial oxidase NOX1 resulting in reactive oxygen species generation and oxidative modification of phosphatases involved in controlling activation/phosphorylation of focal cell matrix adhesion proteins such as focal adhesion kinase (FAK). As shown in Figure 2 , increased phosphorylated FAK is visualized in the migrating epithelial sheet incubated with Ac2-26 (Leoni et al., 2013) . Recently, we also identified woundmucosa-associated microbiota that activate the ANXA1 receptor, FPR1 to promote intestinal mucosal wound repair (Alam et al., 2016) .
Externalization of ANXA1 -and what next?
ANXA1 protein resides on the inner leaflet of the plasma membrane and can be externalized through a number of mechanisms that involve membrane transporters and vesicular trafficking. Perretti and colleagues identified ANXA1 in the gelatin granules of resting neutrophils ( Perretti et al., 2000; Murav'ev et al., 2003) . Following neutrophil adhesion to endothelial cells, gelatinase granules were observed to translocate and fuse with the plasma membrane, leading to the release of ANXA1 in the extracellular compartment and its association with the cell surface (Euzger et al., 1999) . This process was reported to be controlled by ANXA1-binding protein expressed at the cell surface (Goulding et al., 1996) . During an inflammatory response, secreted free-ANXA1 is cleaved by serine proteases with generation of an inactive state that may result in autoantibody production (Pederzoli-Ribeil et al., 2010) . These antibodies may be responsible for neutralizing the protein directly, as well as reducing its levels in the plasma (Yazid et al., 2015) . ANXA1 in the extracellular milieu is localized in EVs that include microparticles (MPs) and membrane-coated vesicles that originate from the plasma membrane (Raposo and Stoorvogel, 2013) . Dalli and coworkers identified ANXA1 containing MPs that are released from activated neutrophils which mediate its anti-inflammatory activity (Dalli et al., 2008) . These results suggest that generation and delivery of ANXA1-rich MPs in the inflamed microcirculation could potentially be used to reduce neutrophil recruitment and promote resolution of inflammation. In addition to MPs, ANXA1 has been identified in smaller EVs referred to as exosomes (40 nm-100 nm) that are derived from the endocytic compartment (Raposo and Stoorvogel, 2013) . ANXA1 is released in exosomes derived from cancer cells as well as from leukocytes and epithelial cell ( Aalberts et al., 2012; Boudhraa et al., 2016) . ANXA1 containing EVs were identified during resolution of colitis and harvested ANXA1 EVs had functional effects in promoting wound repair by activation of FPR1 and FPR2/ALX signaling (Leoni et al., 2015b) . Furthermore, Headland et al. also identified ANXA1 containing EVs in the synovial fluid of patients with rheumatoid arthritis . In addition to mediating a resolution response, ANXA1 containing EVs administered by intra-articular injection had beneficial effects by reducing cartilage degradation and transforming growth factor-beta (TGF-β) signaling in chondrocytes . These studies further highlight the therapeutic potential of using ANXA1 EVs to promote resolution of inflammation and repair. Of additional importance, increased ANXA1 EVs were detected in the circulation during the active stage of mucosal inflammatory disease suggesting that they could also serve as a biomarker of active disease Leoni et al., 2015b) .
Repair and tissue regeneration in injured skeletal myofibers involves fusion of intracellular vesicles with sarcolemma and also fusion of muscle progenitor cells. In vitro studies have identified a role of ANXA1 in both these fusion events. Lack of ANXA1 delays muscle regeneration after injury and lowers the number of differentiating myoblasts (Leikina et al., 2015) . Another study identified ANXA1 peptide cleaved by calpain that is secreted from skeletal muscle cells during contraction and promotes repair (Goto-Inoue et al., 2016) . Systemic levels of proresolving mediators are increased in a number of diverse chronic inflammatory diseases ranging from intestinal disorders, as described above to central nervous system diseases such as Alzheimer's disease. However, in the latter scenario, ANXA1 signaling may be defective (Leoni et al., 2015b; Wang et al., 2015) . ANXA1 receptor, FPR2/ALX expression is decreased in patients with asthma, which might account for the inability of increased ANXA1 to have beneficial effects (Planaguma et al., 2008) .
In the context of leukocyte migration, ANXA1 has been shown to induce L-Selectin shedding on neutrophils and the detachment of adhering leukocytes from the endothelium, by reducing α4β1 integrin clustering and activation (Gavins and Hickey, 2012) . Administration of ANXA1 inhibits neutrophil rolling and capture and the Ac2-26 peptide antagonizes neutrophil adhesion and chemotaxis (Hayhoe et al., 2006) . Recruitment of inflammatory cells from the circulation and their transendothelial migration represents an early phase of atherosclerosis. Administration of ANXA1 mimetic peptide Ac2-26 attenuates early atherogenesis which resultes in reduction of plaques. Drechsler and colleagues demonstrated that Ac2-26 inhibits CCL5-induced switch of β2 integrin conformation into its activated state in neutrophils and monocytes (Drechsler et al., 2015) . Interestingly, Fredman et al. showed that collagen IV (Col IV) -nanoparticles (NPs) containing Ac2-26 targeted to lesions -led to a marked improvement in plaque properties such as reduction of plaque necrosis and oxidative stress and improved stability of advanced atherosclerotic lesions (Fredman et al., 2015) . Kusters and coworkers also demonstrated that ANXA1 treatment suppressed atherogenesis in a murine model of atherosclerosis . These studies further highlight the therapeutic potential of ANXA1 in atherosclerosis.
Recent advances in the understanding of mechanisms underlying both physiological and pathological repair of tissue injury have identify potentially new therapeutic targets to reduce inflammation and associated fibrosis. In addition to promoting resolution of inflammation and repair, ANXA1 has also been shown to influence the fibrotic response that contributes to tissue repair. While ANXA1 biosynthesis and release can be induced by the pro-fibrotic cytokine TGF-β, ANXA1 inhibits the cytokine effects on α-SMA and collagen A1 gene expression. In synovial fibroblasts from patients with rheumatoid arthritis, ANXA1 enhanced secretion of matrix metalloproteinase 1, an enzyme involved in the degradation of extracellular matrix components (Morand et al., 2006; Tagoe et al., 2008; Damazo et al., 2011) . Furthermore, ANXA1 absence in mice is associated with aggravated bleomycin-induced pulmonary fibrosis (Damazo et al., 2011) . Thus, this ligand-receptor interaction may represent a novel therapeutic target to inhibit fibrosis in chronic kidney disease (Neymeyer et al., 2015) . The ANXA1 mimetic peptide Ac2-26 also has beneficial effects on lung function and pathology in mice with silicosis suggesting that it could be used as a therapeutic agent in lung disease (Trentin et al., 2015) .
ANXA1 as modulator of tumortargeting immune strategies
Although advances in new diagnostic tools and treatments have reduced mortality rates, cancer remains a leading cause of death. Recently, Lin and colleagues analyzed 115 patients with oral carcinoma and observed high expression of ANXA1 in the nucleus of epithelial tumor cells (Lin et al., 2008) . ANXA1 expression has been reported to be associated with a highly invasive basal-like breast cancer, a particularly aggressive molecular subtype defined by a robust cluster of genes expressed by epithelial cells in the basal or outer layer of the adult mammary gland. ANXA1 promotes metastasis by enhancing TGFβ/Smad signaling in breast cancer cells (de Graauw et al., 2010) . Up-regulation of ANXA1/FPR2 expression in cancer cells was correlated with down-regulation of inflammatory cytokines (IL-6, IL-8 and MCP-1) and MMP2 (Gastardelo et al., 2014) . Rossi et al. described dysregulated ANXA1 protein expression in pre-cancerous gastric lesions, suggesting its involvement in the early stages of gastric carcinogenesis (Rossi et al., 2014) . Furthermore, it has been shown that ANXA1 is post-transcriptionally regulated by miR-196a in response to VEGF, which contributes to endothelial cell migration (Pin et al., 2012) . Accordingly, the absence of ANXA1 in mice is associated with defects in tumor growth, metastasis and angiogenesis implicating a role of ANXA1 in tumor progression (Murav'ev et al., 2003) .
Technologies are needed to map and image inflammation and also, cancer in vivo. Proteomic and imaging analyses demonstrated that a post-translationally modified form of ANXA1 is selectively concentrated in human and rodent tumor caveolae. To follow trafficking of cancer cells, the authors have designed a specific ANXA1 antibody that targets caveolae in the tumor endothelium; this approach could represent an important tool for future detection of cancer in human patients (Oh et al., 2014) . It is important to keep in mind that the success of anticancer chemotherapy is linked to a durable tumortargeting immune response .
Recent studies confirmed that FPR1 and its ligand, ANXA1, promoted stable interactions between dying cancer cells and leukocytes. Thus, FPR1 and its ligand ANXA1 (and Ac2-26) might contribute to chemotherapy-induced anticancer immune responses (Vacchelli et al., 2015; .
Concluding remarks
In summary, ANXA1 participates in a number of important biological processes that encompass cell migration, recruitment, permeability, apoptosis, phagocytosis and proliferation (Figure 3) . In addition to serving as a biomarker for active inflammation, accumulating evidence supports an important role of ANXA1 in facilitating resolution of inflammation and mucosal wound repair.
